XSHG
603987
Market cap456mUSD
Jul 10, Last price
7.23CNY
1D
1.97%
1Q
-18.12%
Jan 2017
-52.99%
IPO
-8.37%
Name
Shanghai Kindly Enterprise Development Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Kindly Enterprise Development Group Co.,LTD. (603987.SS) is a global manufacturer and distributor of disposable medical polymer products. The company's core offerings include essential medical devices such as syringes, infusion and transfusion sets, various medical tubes, needles, cannulas, and specialized medical bags. Beyond these primary instruments, they supply a comprehensive range of medical packaging materials, including PPPE composite films, dedicated medical packing films, sterilization indicator strips, Bowie Dick test packs, sterilization indicator tapes, medical wrapping papers, paper bags, and sterilization reels. Their extensive portfolio also features interventional accessories crucial for various procedures, encompassing guide wires, Y-connectors, inflation devices, manifold kits, pressure bandages, angiography syringes, stopcocks, sterile Seldinger needles, introducer sets and accompanying tool kits, pressure transducers, extension tubes, hemostasis balloons, extension lines equipped with needle-free valves, pressure monitoring tubing products, and spine tool kits. Furthermore, they provide a variety of catheters, including guiding, micro, and angiography catheters. Additional products comprise self-sealing pouches, Tyvek® reels, mini-spikes, PE extension tubes, and essential accessories like heparin caps, umbilical cord clamps, and safety boxes. The company also furnishes pre-packaged medical solutions, including suction catheter kits, irrigation kits, and puncture sets. Founded in 1987, Shanghai Kindly Enterprise Development Group Co.,LTD. maintains its headquarters in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||